QualityStocksNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Preclinical Data Demonstrating Differentiated Mechanism of Action of PH10 from Benzodiazepines
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced promising preclinical data for its PH10 drug candidate. The data demonstrate that the potential mechanism of action of PH10, VistaGen’s Phase 2 investigational pherine nasal spray with potential as a rapid-onset, stand-alone treatment for major depressive disorder (“MDD”), does not involve direct activation of GABA-A receptors. This is in distinct contrast to the mechanism of action of benzodiazepines, which act as direct positive modulators of GABA-A receptors. Instead, PH10 is designed to engage receptors in nasal chemosensory neurons,…